High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes

Biomedical Chromatography

Volumn 15, Issue 5, 2001, Pages 328-333

  Hanioka, Nobumitsu ^a   Jinno, Hideto ^a   Nishimura, Tetsuji ^a   Ando, Masanori ^a   Ozawa, Shogo ^a   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITES; THIN LAYER CHROMATOGRAPHY;

ACTIVE METABOLITES; GLUCURONIDATION; GLUCURONIDES; HUMAN LIVER MICROSOMES; HYDROXYCAMPTOTHECIN; IRINOTECAN; LIQUID CHROMATOGRAPHIC ASSAY; PERFORMANCE; SENSITIVE ASSAY; SIMPLE++;

DRUG INTERACTIONS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CAMPTOTHECIN DERIVATIVE; ENZYME; GLUCURONOSYLTRANSFERASE; IRINOTECAN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CALIBRATION; CHEMICAL REACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG GLUCURONIDATION; DRUG INTERACTION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME KINETICS; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LINEAR SYSTEM; LIVER MICROSOME; LOW TEMPERATURE; METHODOLOGY; MOLECULAR STABILITY; SIDE EFFECT; THERMOSTABILITY; THIN LAYER CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 0034869067     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.76     Document Type: Article

References (22)

1. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11
2. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
3. UDP-glucuronosyltransferases
4. The structure and function of the UDP-glucuronosyltransferase gene family
5. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
6. Topoisomerase I inhibitors: Topotecan and irenotecan
7. Glucuronidation of Drugs and Other Compounds
8. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
9. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
10. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
11. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
12. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
13. Production of SN-38, a main metabolite of the camptothecin derivative CPT-11, and its species and tissue specificities
14. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma on-line solid-phase extraction system. PROSPEKT
15. Protein measurement with the folin phenol reagent
16. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
17. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
18. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin
19. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
20. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
21. Glucuronidation in humans: Pharmacogenetic and developmental aspects
22. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer